EREric M. Reiman

Eric M. Reiman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years

Recognitions

Top Cited Scholar (2026)

Eric M. Reiman has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A revised visual grading scale of the cavum septi pellucidi in contact-collision sport athletes with repetitive head impacts

    by Anya S. Mirmajlesi, Jared Stearns, Brian Szekely, Manuel Estrada, Rebecca D. Folkerth, Sylvain Bouix, Daniel H. Daneshvar, Charles H. Adler, Charles Bernick, Laura J. Balcer, et al.

  • Centrally Acting Medications, Chronic Pain, and Orthopedic Surgical History Among Former American Football Players

    by Alexa Puleio, Ina Hoti, William B. Barr, Sarah J. Banks, Jennifer Voreis Wethe, Yorghos Tripodis, Charles H. Adler, Laura J. Balcer, Charles Bernick, David W. Dodick, et al.

  • Open Access

    Returning APOE and pTau-217 Results: the eSMARTER Randomized Noninferiority Clinical Trial

    by Jessica B. Langbaum, Claire M. Erickson, Carolyn Langlois, Elisabeth M. Wood, Brian L. Egleston, Kristin Harkins, Rajia Mim, Samantha John, Camille Brown, Sarah Brown, et al.

    Importance: Patients are increasingly learning Alzheimer’s disease (AD) genetic and biomarker results through electronic health portals. Evaluation of alternative scalable delivery models for return of AD risk information is needed to best support patient understanding and psychological well-being. Objective: To determine whether a patient-centered digital platform is comparable to clinician-mediated telehealth sessions for returning APOE and plasma pTau-217 results on outcomes of knowledge and psychological well-being. Design: The Evaluation of Self-Mediated Alternatives for Risk Testing Education and Return of Results (eSMARTER) study was a noninferiority trial of a patient-centered digital platform compared to clinician-mediated disclosure of APOE genotype and optional pTau-217 disclosure. Setting: Decentralized, fully remote trial enrolled participants in the contiguous United States (U.S.) between October 2024 and February 2025, with follow-up completed in November 2025. Participants: Eligible participants were aged 60-80 and had previously undergone APOE genotyping (without disclosure) via the GeneMatch program, passed psychological screening, had internet access, and were English-speaking. Interventions: Participants were randomized, 2:1, to the eSMARTER digital platform or clinician-mediated disclosure of APOE genotype. Following the 6-month post- APOE assessment, participants were offered optional pTau-217 disclosure via the same randomized modality. Main Outcomes and Measures: Primary outcomes at 1-7 days following APOE disclosure included changes in anxiety, disease-specific distress, and AD-related knowledge within a priori non-inferiority margins. Results: 674 persons (mean [SD] age 68 [4.7] years; 451 [67%] female; mean [SD] telephone MoCA=19 [2]) were eligible and provided demographic information. 651 participants were randomized to clinician-mediated (n=216) or digital disclosure (n=435) and completed APOE disclosure (66 [10%] APOE4 homozygotes, 377 [58%] heterozygotes, 208 [32%] non-carriers). 604 participants completed the study; 500 completed optional pTau-217 disclosure. Baseline characteristics were balanced across groups. At 1-7 days following APOE disclosure, scores on AD-related knowledge, PROMIS Anxiety, and disease-specific distress measures met non-inferiority. Conclusions and Relevance: Disclosure of APOE genotype by the eSMARTER digital platform is non-inferior to clinician-mediated telehealth disclosure. No significant between group differences were found following disclosure of pTau-217 results. Together, these results suggest that this digital platform may provide an evidence-based scalable approach for returning AD genetic and biomarker results. Trial Registration: ClinicalTrials.gov Identifier NCT06459583

  • Open Access

    Baseline and placebo-related imaging, cerebrospinal fluid, plasma biomarker, and cognitive findings in unimpaired PSEN1 E280A mutation carriers and non-carriers in the Alzheimer’s Prevention Initiative Autosomal Dominant Alzheimer’s Disease Colombia Trial

    by Tobias Bittner, Francisco Lopera, Silvia Rios-Romenets, Courtney Schiffman, David Clayton, Derrek Hibar, Gwendlyn Kollmorgen, Michael Dolton, Victor Poon, Jonas Nguyen, et al.

  • Open Access

    Effect of Intensive vs Standard Blood Pressure Control According to APOE ε4 Genotype: A Secondary Analysis of SPRINT

    by Yizhe Xu, Jeremy J. Pruzin, Tom Greene, Jeff Williamson, David M. Reboussin, Nicholas M. Pajewski, Michael Klein, Wai-YingWendy Yau, Eric M. Reiman, Mark A. Supiano, et al.

    Importance: Apolipoprotein E ( APOE ) ε4 is the strongest genetic risk factor for sporadic dementia, yet whether the benefits of intensive systolic blood pressure (SBP) control differ by APOE ε4 carrier status remains unknown. This is among the first randomized evaluations of intensive SBP control on all-cause dementia by APOE ε4 status in US adults without diabetes. Objective: To compare effects of intensive vs standard SBP control on incident all-cause probable dementia between APOE ε4 carriers and non-carriers. Design, Setting, and Participants: Secondary analysis of the Systolic Blood Pressure Intervention Trial (SPRINT), a multicenter randomized trial of adults >50 years with hypertension and increased cardiovascular risk, but without diabetes, prior stroke, or dementia. Primary cognitive follow-up ended July 2018. Participants were further followed with telephone-based outcome assessment from 2019 through 2023. Interventions: Intensive SBP control (goal APOE ε4 status was the primary effect modifier. Results: Of 9,361 randomized participants, 8,390 (89.6%) had APOE genotyping (29% ε4 carriers); 7,733 (82.6%) had both genotype and outcome data (mean age, 68 years; 36% female; 28% Non-Hispanic Black). Over a median follow-up of 5.1 years, dementia rates (intensive vs standard) were 9.7 vs 13.2 per 1,000 person-years among ε4 carriers (hazard ratio [HR], 0.73; 95% CI, 0.51-1.04) and 6.1 vs 6.7 among non-carriers (HR, 0.91; 95% CI, 0.67-1.23; P-interaction = .35). Four-year risk differences were −1.7% (95% CI, −3.4% to 0%; number needed to treat, 59) among carriers and 0.2% (95% CI, −0.6% to 1%) among non-carriers (P-interaction = .045). Patterns were similar for the composite of MCI or dementia; effects on MCI were similar between APOE ε4 subgroups. Conclusions and Relevance: Among US adults at high cardiovascular risk, intensive SBP control yielded larger absolute risk reduction in dementia among APOE ε4 carriers than non-carriers; relative effects were similar. These findings may inform APOE ε4-stratified blood pressure management for dementia prevention. KEY POINTS: Question: What is the effect of intensive vs standard systolic blood pressure (SBP) control on incident dementia by APOE ε4 status? Findings: In SPRINT, intensive vs standard SBP control yielded a significantly larger 4-year absolute risk reduction in dementia among APOE ε4 carriers (−1.7%) than non-carriers (0.2%; P-interaction = .045); the relative-scale interactions were directionally consistent but not significant. Meaning: Among US adults at high cardiovascular risk, intensive SBP control yielded larger absolute benefit among APOE ε4 carriers than non-carriers; relative benefits were similar. APOE ε4 status may inform risk-stratified blood pressure management for dementia prevention.

  • Open Access

    Cognitive, biomarker, and neuroimaging indices associated with traumatic encephalopathy syndrome across two independent athlete cohorts

    by Brooke D. Conway Kleven, Lung-Chang Chien, Dana Surwill, Michael L. Alosco, Jennifer V. Wethe, Yorghos Tripodis, Charles H. Adler, Martha E. Shenton, Ofer Pasternak, Douglas I. Katz, et al.

    Traumatic encephalopathy syndrome (TES) is a clinical research construct used to identify individuals at risk for chronic traumatic encephalopathy (CTE) fo


  • Inflammation, Limbic White Matter Microstructure, and Clinical Symptoms in Retired American Football Players With Repetitive Head Impacts

    by Olivia M. Emanuel, Annalise E. Miner, Shannon Y. Lee, Emily F. Matusz, Jared J. Tanner, Michael Marsiske, Allison Holgerson, Monica T. Ly, Fatima Tuz-Zahra, Yorghos Tripodis, et al.

    The link between repetitive head impact (RHI) exposure, later-life cognitive decline, and neurobehavioral dysregulation (NBD) is not well understood. Recent work has implicated inflammation and limbic dysfunction as relevant RHI correlates. Our goal was to integrate plasma and CSF inflammatory biomarkers, structural brain imaging, and clinical measures in former elite American football players to better understand reasons for RHI-related cognitive and neurobehavioral changes. Participants were from the Diagnostics, Imaging, and Genetics Network for the Objective Study and Evaluation of Chronic Traumatic Encephalopathy Research Project, which recruited male former college/professional football players with RHI and asymptomatic unexposed (UE) controls with no history of contact sports, military combat, or traumatic brain injury/concussion. Our study focused on plasma/CSF inflammatory biomarkers (interleukin [IL]-6, tumor necrosis factor [TNF]-α, glial fibrillary acidic protein), limbic white matter (WM) microstructure (diffusion tensor imaging: fractional anisotropy [FA], mean diffusivity [MD]), and clinical measures (memory, executive function, NBD). Hierarchical linear regressions assessed change in variance explained (ΔR2) among inflammation, WM, and clinical outcomes in former football players. Post hoc analyses tested whether associations differed by group (football vs UE; group interactions) or were stronger in football players considered at highest risk of CTE. Our sample included 223 men (n = 170 football players: age 57.2 ± 8.1 years, 33% non-Hispanic/Black; n = 53 UE participants: age 59.4 ± 8.6 years, 34% non-Hispanic/Black). In football players, higher inflammation was associated with lower limbic FA (plasma IL-6: ΔR2 = 0.03 [0.001-0.09], p = 0.03; CSF IL-6: ΔR2 = 0.03 [-0.01 to 0.11], p = 0.03; plasma TNF-α: ΔR2 = 0.05 [0.01-0.11], p = 0.003) and higher limbic MD (CSF IL-6: ΔR2 = 0.06 [0.007-0.15], p = 0.01). Inflammation was more strongly related to limbic WM microstructure in football players than in UE participants. Worse WM microstructure was associated with worse memory in football players (FA: ΔR2 = 0.05 [0.003-0.14], p = 0.007; MD: ΔR2 = 0.07, p = 0.003 [0.008-0.16]). Most of the observed associations were stronger in the CTE probable subgroup. There were no direct associations between plasma or CSF markers of inflammation and cognition. In former elite football players, elevated plasma and CSF inflammatory markers were associated with poorer limbic WM microstructure, which in turn related to worse cognition. Given the limbic system's role in cognition and behavior, inflammation may be a modifiable target for RHI-related neurodegeneration. Limitations include the cross-sectional design and limited generalizability to other contact sports, lower levels of play, female athletes, or other RHI sources.


  • Clarifications on our Policy View

    by Eric M Reiman, Robert C Alexander, Jessica B Langbaum, Jeffrey L Cummings

  • A path to preventing cognitive impairment due to Alzheimer's disease: initiatives beginning in the USA

    by Eric M Reiman, Robert C Alexander, Jessica B Langbaum, Paul S Aisen, Nicholas Ashton, Alireza Atri, Paola Barbarino, Goldie S Byrd, Howard H Feldman, Nicole R Fowler, et al.


  • Open Access

    TAS2R38 Taster Variants-Linked MGAM Expression in Alzheimer’s Disease: A Novel Target for Precision Drug Repurposing

    by Claire Su, Kewei Chen, Teresa Wu, Eric Reiman, Qi Wang

    Objective TAS2R38 is a taste receptor implicated in innate immunity. Identifying its genetic connection with Alzheimer’s disease (AD) could aid in developing new drugs or repurposing existing ones for treatment. Methods We examined the relationship between TAS2R38 taster variants and AD risk using linear mixed-effects models, utilizing data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (n = 2,342). We investigated molecular mechanisms of the association by identifying expression quantitative trait loci (eQTLs) using RNA-seq data from postmortem tissues from the Religious Orders Study/Memory and Aging Project (ROSMAP) (n = 947). We evaluated whether FDA-approved drugs targeting the identified gene could reduce dementia risk using 1:1 propensity score-matched groups in the National Alzheimer’s Coordinating Center (NACC) study, comparing cognitive performance between drug-taking and non-taking patients with linear mixed-effects models (n = 76). Results TAS2R38 supertasters were linked to reduced AD risk with advancing age in various AD biomarkers (P < 0.001). eQTL analysis connected the nontaster allele to increased expression of the gene MGAM in AD-affected brain regions (P < 0.001). Elevated MGAM expression was also associated with more severe Tau burdens (P < 0.05). A significant group difference was observed in clinical dementia rating (CDR) progression (P < 0.001) in various domains for individuals taking MGAM-inhibiting diabetes drugs (Acarbose and Miglitol) compared to the non-taking group. Interpretation The genetic association between TAS2R38 and AD biomarkers implicates MGAM as a novel drug target with existing FDA-approved inhibitors. This supports the potential of TAS2R38 haplotypes in guiding precision drug repurposing strategies for AD, warranting clinical trials.